April 21, 2025 – Talk Bio

Immunovant Refines R&D Strategy with New Leadership

3 days ago talkbio0Tagged Changing, Focal, Immunovant, Leadership, Roivant

Immunovant, Roivant, R&D Focus, Leadership Changes, IMVT-1402

AstraZeneca, Daiichi say Enhertu delivers ‘highly statistically significant’ efficacy in first-line breast cancer

3 days ago talkbio0Tagged Antibodies, Antibody-Drug Conjugates, AstraZeneca, Daiichi, deruxtecan-nxki, Enhertu, fam-trastuzumab, first-line therapy, HER2-positive metastatic breast cancer, pertuzumab, Progression-Free Survival, Sankyo

Enhertu, fam-trastuzumab deruxtecan-nxki, AstraZeneca, Daiichi Sankyo, HER2-positive metastatic breast cancer, first-line therapy, progression-free survival, antibody drug conjugate (ADC), pertuzumab

Chinese CRO GemPharmatech expands in San Diego as industry weighs FDA’s animal testing shift

3 days ago talkbio0Tagged Animal Testing, Contract Research Organization, expansion, GemPharmatech, Industry, mouse models, San Diego, United States Food and Drug Administration

United States Food and Drug Administration, GemPharmatech, Contract Research Organization, San Diego, Animal Testing, mouse models, expansion, Industry

FDA rejection of extended dosing interval is another piece of bad news for Regenerons Eylea HD

3 days ago talkbio0Tagged Age related macular degeneration, Diabetic Retinopathy, dosing, Extension, Eylea HD, Interval, Regeneron, Rejection, United States Food and Drug Administration

United States Food and Drug Administration, Interval, Regeneron, dosing, Extension, Eylea HD, rejection, Age related macular degeneration, Diabetic Retinopathy